Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (171)	4/8/1998 2:23:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3044

>> Worth keeping an eye on - maybe we should take this discussion to the relevant thread <G>. << Got ya. Just a quick comment.... I visited both CBST and MCDE last Spring, CBST with Jim Silverman and MCDE with John Dwyer. I also attended both presentations at this year's H&Q. While I like both companies at these market caps and feel very much at home with Rurka, CBST fought, through tough times, to keep on track while MCDE wandered. Disclaimer..... own MCDE, thinking about buying CBST. Rick

To: Biomaven who wrote (171)	4/8/1998 10:20:00 PM
From: John O'Neill	Read Replies (3) \| Respond to of 3044

MCDE expected to meet all expenses from it's cash flow for next 5 years. In addition, they have about $3.50/ share cash which they can hold onto for after the 5 year period. Exceptional cash flow for a biotech...!! I expect a LOT of publicity about resistant bacteria. This can truly become a panic situation..I have already begun to see this in the hospitals and skilled nursing facilities. Bacteria share resistant genes and we're heading for trouble unless new approaches are forthcoming soon. Curing cancer would be a blessing, but if John Doe worker starts dropping dead of simple strep/staph this would attract attention not yet seen in the drug world. We have taken our antibiotics for granted; infections accounted for more than 1/2 of fatalities before penicillin was developed. Forbes just had article April 6 & MCDE was at the top of it's short list. JO